-
Je něco špatně v tomto záznamu ?
New series of isoniazid hydrazones linked with electron-withdrawing substituents
Eva Vavříková, Slovenko Polanc, Marijan Kočevar, Janez Košmrlj, Kata Horváti, Szilvia Bősze, Jiřina Stolaříková, Aleš Imramovský, Jarmila Vinšová
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NS10367
MZ0
CEP - Centrální evidence projektů
- MeSH
- antibakteriální látky chemie farmakologie MeSH
- antituberkulotika chemie farmakologie MeSH
- atypické mykobakteriální infekce farmakoterapie MeSH
- buňky Hep G2 MeSH
- hydrazony chemie farmakologie MeSH
- intracelulární infekce bakterií Mycobacterium avium farmakoterapie MeSH
- isoniazid chemie farmakologie MeSH
- lidé MeSH
- mikrobiální testy citlivosti MeSH
- Mycobacterium avium komplex účinky léků MeSH
- Mycobacterium kansasii účinky léků MeSH
- Mycobacterium tuberculosis účinky léků MeSH
- tuberkulóza farmakoterapie MeSH
- viabilita buněk účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
A series of new isoniazid hydrazones was synthesized by two procedures. In the first isoniazid was activated with diethoxymethyl acetate and condensed with the appropriate anilines. Alternatively, substituted anilines were activated by diethoxymethyl acetate and subsequently condensed with isoniazid. NMR study confirmed that both synthetic approaches gave the same tautomer. All compounds were screened for in vitro antimycobacterial activity. Most of them exhibited the same activity against Mycobacterium tuberculosis (MIC 1 μmol L(-1)) as isoniazid (INH), better activity against Mycobacterium kansasii 325/80 (MIC 0.125-0.250 μmol L(-1)), high value of selectivity index (SI) and IC(50) between 0.0218 and 0.326 mmol L(-1). Compound 2o with the best SI was used as a model compound for the stability test and was found to be stable at neutral pH, but under acidic conditions it slowly hydrolysed.
Eötvös Loránd University Research Group of Peptide Chemistry Hungarian Academy of Science Hungary
Institute of Public Health Centre of Hygienic Laboratories Ostrava Czech Republic
University of Ljubljana Faculty of Chemistry and Chemical Technology Ljubljana Slovenia
University of Pardubice Faculty of Chemical Technology Pardubice Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12022268
- 003
- CZ-PrNML
- 005
- 20160329145402.0
- 007
- ta
- 008
- 120806s2011 fr f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2011.09.054 $2 doi
- 035 __
- $a (PubMed)22018878
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Vavříková, Eva $7 xx0126311 $u Charles University, Faculty of Pharmacy, Department of Inorganic and Organic Chemistry, Hradec Králové, Czech Republic
- 245 10
- $a New series of isoniazid hydrazones linked with electron-withdrawing substituents / $c Eva Vavříková, Slovenko Polanc, Marijan Kočevar, Janez Košmrlj, Kata Horváti, Szilvia Bősze, Jiřina Stolaříková, Aleš Imramovský, Jarmila Vinšová
- 520 9_
- $a A series of new isoniazid hydrazones was synthesized by two procedures. In the first isoniazid was activated with diethoxymethyl acetate and condensed with the appropriate anilines. Alternatively, substituted anilines were activated by diethoxymethyl acetate and subsequently condensed with isoniazid. NMR study confirmed that both synthetic approaches gave the same tautomer. All compounds were screened for in vitro antimycobacterial activity. Most of them exhibited the same activity against Mycobacterium tuberculosis (MIC 1 μmol L(-1)) as isoniazid (INH), better activity against Mycobacterium kansasii 325/80 (MIC 0.125-0.250 μmol L(-1)), high value of selectivity index (SI) and IC(50) between 0.0218 and 0.326 mmol L(-1). Compound 2o with the best SI was used as a model compound for the stability test and was found to be stable at neutral pH, but under acidic conditions it slowly hydrolysed.
- 650 _2
- $a antibakteriální látky $x chemie $x farmakologie $7 D000900
- 650 _2
- $a antituberkulotika $x chemie $x farmakologie $7 D000995
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a buňky Hep G2 $7 D056945
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydrazony $x chemie $x farmakologie $7 D006835
- 650 _2
- $a isoniazid $x chemie $x farmakologie $7 D007538
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 _2
- $a atypické mykobakteriální infekce $x farmakoterapie $7 D009165
- 650 _2
- $a Mycobacterium avium komplex $x účinky léků $7 D015269
- 650 _2
- $a intracelulární infekce bakterií Mycobacterium avium $x farmakoterapie $7 D015270
- 650 _2
- $a Mycobacterium kansasii $x účinky léků $7 D019909
- 650 _2
- $a Mycobacterium tuberculosis $x účinky léků $7 D009169
- 650 _2
- $a tuberkulóza $x farmakoterapie $7 D014376
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Polanc, Slovenko $u University of Ljubljana, Faculty of Chemistry and Chemical Technology, Ljubljana, Slovenia
- 700 1_
- $a Kočevar, Marijan $u University of Ljubljana, Faculty of Chemistry and Chemical Technology, Ljubljana, Slovenia
- 700 1_
- $a Košmrlj, Janez $u University of Ljubljana, Faculty of Chemistry and Chemical Technology, Ljubljana, Slovenia
- 700 1_
- $a Horváti, Kata $u Eötvös Loránd University, Research Group of Peptide Chemistry, Hungarian Academy of Science, Hungary
- 700 1_
- $a Bosze, Szilvia $u Eötvös Loránd University, Research Group of Peptide Chemistry, Hungarian Academy of Science, Hungary
- 700 1_
- $a Stolaříková, Jiřina $7 xx0142458 $u Institute of Public Health, Centre of Hygienic Laboratories, Ostrava, Czech Republic
- 700 1_
- $a Imramovský, Aleš $7 xx0118877 $u University of Pardubice, Faculty of Chemical Technology, Pardubice, Czech Republic
- 700 1_
- $a Vinšová, Jarmila, $d 1951- $7 nlk19990073991 $u Charles University, Faculty of Pharmacy, Department of Inorganic and Organic Chemistry, Hradec Králové, Czech Republic
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 46, č. 12 (2011), s. 5902-5909
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22018878 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120806 $b ABA008
- 991 __
- $a 20160329145434 $b ABA008
- 999 __
- $a ok $b bmc $g 944181 $s 779565
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 46 $c 12 $d 5902-5909 $e 20111013 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- GRA __
- $a NS10367 $p MZ0
- LZP __
- $b NLK111 $a Pubmed-20120806/12/01